Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
PMID: 30906435
2019
Experimental and therapeutic medicine
Abstract: Furthermore, although in the non-responder group the frequency of the LAM resistance-associated mutations (rtM204V/I) decreased at 6 months compared with the baseline, it did not disappear in any of the patients after six months of treatment.
Abstract: In the present study, 16 Discussion: Similar to previous studies, the present study suggested that truncation mutations (rtA181T/sW172*, rtM204I/sW196* and rtV191I/sW182*) occurred at the highest frequency.
[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.
[Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Abstract: Notably, 11 mutations at position 169, 202, 250, 173, 180, 200, 207, 214, 237, 242 and 245 coexisted with M204I or V.
Discussion: For L-nucleosides resistance, M204I/V was the most critical mutation site.
Discussion: However, L180 + M204I formed the basis of ETV resistance, which together with the higher mutation rates at other three ETV-resistant mutation sites (180, 200 and 202) in genotype C (Table 3), contributed to more favorable for further evolution towards ETV resistance in genotype C.
Discussion: In current study, mutation of L229 was not a single mutation site: 75% mutations of this site associated to M204I or V.
Discussion: Our data showed no significant difference was found in frequencies of M204I or V mutation.
Discussion: reported that an combined mutati
Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naive chronically infected patients.
Abstract: Drug resistance conferring substitutions (DRCSs) were rtL180M (22/98), rtA194V (11/98), rtM204V (1/98), and rtM204I (11/98).
Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Introduction: For instance, I195M in the S protein (sI195M) and sW196S can produce rtM204I and rtL180M/rtM204I in RT, which could confer resistance to LMV.
Introduction: For instance, M204V/I in RT (rtM204V/I) is a classical lamivudine (LMV) resistance mutation, which also greatly reduces susceptibility to telbivudine (LdT); rt
Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs.
Abstract: In the present study, HBV genomes with frequently detected reverse transcriptase (RT)/surface truncation MTs, rtA181T/sW172*, rtV191I/sW182* and rtM204I/sW196*, were phenotypically characterized alone or together with their WT counterparts in different ratios by transient transfection in the absence or presence of NAs.
Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Result: No mutations known to cause tenofovir resistance (L180M, A181I/V, A194T, M204V/I, V214A, Q215S, N236T) or lamuvudine (3TC) resistance (L80V/I, I169T, V173L, L180M, A181T, T184S, M204V/I/S, Q215S) were observed.
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
PMID: 31543688
2019
World journal of gastroenterology
Introduction: For instance, rtM204I is a classic mutation reducing susceptibility to mono-therapy by NAs with low genetic barriers, such as lamivudine (LAM), telbivudine (L-dT) and clevudine (CLV).
Introduction: Multivariate analyses showed that the naturally-occurring rtM204I variants were more frequently pre-existed in patients with liver fibrosis, and the pre-existence of the naturally-occurring rtM204I variants were significantly associated with incomplete viral response to nucleos(t)ide analogues.
Introduction: Tenofovir is a more suitable nucleos(t)ide analogues than entecavir for treatment-naive CHB patients carrying the naturally occurring
Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018.
Introduction: A total of 8 HBV classical mutation sites are conventionally tested for HBV patients in most clinical labs, including M204I/V, L180M, T184A/F/I/L/S, L181T/V, M250I/L/V, M236T, Discussion: Combinational mutation occurrences were mainly L180M + M204I/V.
Discussion: The results showed that the HBV mutation rtM204I/V together with rtL180M were the three mutations with the highest incidence, thus demonstrating that LAM-resistance and LdT were the most common resistances in Shenzhen.
HBV mutation literature information.
PMID: 
2019
Experimental and therapeutic medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT